Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
DexTech Medical AB is a biotechnology company specialized in developing new formulations for the treatment of cancer. The company's primary focus is on urological conditions, providing innovative therapies to address unmet clinical needs in prostate cancer treatment. DexTech Medical is known for its groundbreaking research and development centered on its unique water-soluble dextran-based carrier system, which enhances the delivery and efficacy of chemotherapeutic agents. Operating within the highly specialized biotech sector, the company's advancements contribute to significant improvements in therapeutic outcomes and patient care. DexTech Medical's market presence is defined by its commitment to advancing cancer treatments through scientific innovation, making it a significant player in the biotechnology and pharmaceutical industries.
kr 0.88
+kr 0.02 (+2.56%)
EOD Jun 23, 2026 · Twelve Data
Negative free cash flow of -kr 4M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 0.00
Net Income (TTM)
-kr 6M
▼ -3.0% YoY
Op. Margin
—
ROIC
-15.46%
▼ -1.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-kr 5M
▲ +30.0% YoY
Op. Cash Flow (TTM)
-kr 5M
▲ +3.6% YoY
Net Debt
-kr 15M
Net Cash Position
Cash & Equiv.
kr 15M
Continue Research
DexTech Medical AB (DEX.XSTO)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, DexTech Medical AB scores 10/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
DexTech Medical AB scores 10 out of 100 on Intrinsiqq's quality score, passing 1 of 4 checks, which makes it a lower-quality business on these measures. Recent fundamentals include a -15.5% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full check-by-check breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh DEX.XSTO's valuation and scores 10/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.